First Drug Approved for Binge-Eating Disorder

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

Lisdexamfetamine dimesylate (Vyvanse), previously approved for treating attention-deficit hyperactivity disorder, is now approved to treat binge-eating disorder in adults. The central nervous system stimulant is the first drug approved for this condition.

In two placebo-controlled trials among some 700 adults with moderate-to-severe binge-eating disorder, those taking daily lisdexamfetamine dimesylate experienced reductions in binge-eating days per week and obsessive-compulsive binge-eating behaviors. The most common side effects included dry mouth, insomnia, increased heart rate, constipation, and anxiety.

Lisdexamfetamine dimesylate is associated with increased risks for sudden death, stroke, myocardial infarction, and psychiatric problems including mania. In addition, it is classified as a schedule II substance because it carries a high potential for abuse.